Lodoco is the first anti-inflammatory approved for reducing cardiovascular events in ASCVD patients.Bempedoic acid offers an alternative for high-risk patients who can't tolerate statins.Semaglutide has emerged as a powerful tool for reducing cardiovascular events in overweight or obese patients with pre-existing CVD.Recaticimab is a long-acting injectable PCSK9 inhibitor requiring less frequent dosing than existing options.Focus on LDL Cholesterol: New data supports the "power of zero" for coronary artery calcium, prioritizing LDL reduction only in those with established atherosclerosis.Treat-to-Target vs. High-Intensity Statins: A study (LODESTAR) shows the non-inferiority of the treat-to-target approach, adding to ongoing discussions about cholesterol management strategies.Shift towards prevention: 2023 saw a significant focus on research and interventions aimed at preventing cardiovascular disease rather than solely treating established cases.Emphasis on early intervention: Studies like POP-HT highlight the importance of monitoring and modifying risk factors in young adulthood.
View all episodes
